We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Johnson & Johnson (JNJ) Com Stk USD 1 (CDI)

Sell:$161.56 Buy:$161.60 Change: $0.40 (0.25%)
Market closed |  Prices as at close on 28 February 2024 | Switch to live prices |
Ex-dividend
Sell:$161.56
Buy:$161.60
Change: $0.40 (0.25%)
Market closed |  Prices as at close on 28 February 2024 | Switch to live prices |
Ex-dividend
Sell:$161.56
Buy:$161.60
Change: $0.40 (0.25%)
Market closed |  Prices as at close on 28 February 2024 | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

Contact details

Address:
One Johnson & Johnson Plaza
NEW BRUNSWICK
08933
United States
Telephone:
+1 (732) 5242455
Website:
https://www.jnj.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
JNJ
ISIN:
US4781601046
Market cap:
$387.31 billion
Shares in issue:
2.41 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
Dow Jones Industrial Average

Key personnel

  • Joaquin Duato
    Chairman of the Board, Chief Executive Officer
  • Joseph Wolk
    Chief Financial Officer, Executive Vice President
  • Peter Fasolo
    Chief Human Resource Officer, Executive Vice President
  • Kathryn Wengel
    Executive Vice President, Chief Technical Operations and Risk Officer
  • James Swanson
    Executive Vice President, Chief Information Officer
  • Elizabeth Forminard
    Executive Vice President, General Counsel
  • Vanessa Broadhurst
    Executive Vice President - Global Corporate Affairs
  • William Hait
    Executive Vice President, Chief External Innovation and Medical Safety Officer, Interim Head Janssen Research and Development
  • John Reed
    Executive Vice President - Pharmaceuticals, R&D
  • Tim Schmid
    Executive Vice President, Worldwide Chairman of MedTech

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.